Skip to main content

Becton Dickinson Value Stock - Dividend - Research Selection

Becton dickinson

ISIN: US0758871091 , WKN: 857675

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Becton Dickinson & Co. stock rises Friday, still underperforms market

2025-04-11
Becton Dickinson & Co. stock rises Friday, still underperforms market

BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know

2025-04-10
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.

Becton Dickinson & Co. stock outperforms competitors despite losses on the day

2025-04-10
Becton Dickinson & Co. stock outperforms competitors despite losses on the day

Becton Dickinson & Co. stock rises Wednesday, still underperforms market

2025-04-09
Becton Dickinson & Co. stock rises Wednesday, still underperforms market

Becton Dickinson and : BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution

2025-04-09
Integration of BD Phoenix™ Automated Microbiology System, BDXpert™ System and BD Synapsys™ Informatics Solution Supports Accurate Detection of Antimicrobial Resistance FRANKLIN...

BD Seeks Potential Buyers for Life Sciences Business Division

2025-04-08
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.

Becton Dickinson & Co. stock underperforms Monday when compared to competitors

2025-04-07
Becton Dickinson & Co. stock underperforms Monday when compared to competitors

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

2025-04-07
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should You be Confident in Becton, Dickinson and Company’s (BDX) Ability to Deliver Long-Term Returns?

2025-04-04
Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm is not a momentum investor and avoids companies with uncertain future earnings and high valuations. The firm invests for the long-term and remains curious about new companies. […]

BD to Announce Financial Results for its Second Quarter of Fiscal 2025

2025-04-03
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the Company's financial results for its second quarter of fiscal year 2025, which ended on March 31, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available sh